Answers are grounded in this paper and cite their sources.
Metabolic syndrome (MetS) is increasingly diagnosed in children, and gut microbiota alterations have been proposed as markers of cardiometabolic risk. However, findings across pediatric studies are inconsistent, with different taxa reported across populations and, in some cases, opposite directions of association. Whether this reflects biological heterogeneity or analytical variation is untested. We hypothesized that a robust microbial signature would re-emerge once analytical differences were removed. Following PRISMA 2020, we screened 154 records and identified three eligible public pediatric fecal 16S rRNA datasets from the USA, China, and Mexico (149 children, 64 with MetS). Raw reads were reprocessed through a unified pipeline, genus-level effects were estimated with a compositionally aware model, and effects for 61 shared genera were pooled by random-effects meta-analysis and evaluated against a pre-specified reproducibility classification benchmarked to chance. Of 24 genera significant within individual cohorts, none replicated in a second cohort. Among ten comparable genera, effects fell by 87% outside the discovery cohort, and no pooled association remained significant after false discovery rate correction. Cross-cohort direction concordance (26.2%) matched chance (25%), and cohort yield did not track sample size. Fixed microbiome biomarker panels are premature, but useful biomarkers are not excluded; larger, better-powered harmonized studies are needed.
No takes yet. Share an insight, caveat, or question.
Abdelfattah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: